Antiprion action of new cyclodextrin analogues

Biochimica et Biophysica Acta - General Subjects

Volumn 1790, Issue 10, 2009, Pages 1382-1386

  McEvoy, Karl ^a   McMahon, Hilary E M ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Cyclodextrin; Prion; Scrapie

Indexed keywords

2 CARBOXYETHYL BETA CYCLODEXTRIN; 2 HYDROXYPROPYL BETA CYCLODEXTRIN; 6 O ALPHA MALTOSYL BETA CYCLODEXTRIN; ACETYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; CARBOXYL BETA CYCLODEXTRIN; HEPARIN; HYDROXYETHYL BETA CYCLODEXTRIN; METHYL BETA CYCLODEXTRIN; QUATERNARY BETA CYCLODEXTRIN; SUCCINYL BETA CYCLODEXTRIN; SULFATED BETA CYCLODEXTRIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG STRUCTURE; HYDROPHOBICITY; IC 50; NONHUMAN; PRIORITY JOURNAL; SCRAPIE; STRUCTURE ANALYSIS;

ANIMALS; ANTICOAGULANTS; BETA-CYCLODEXTRINS; BLOTTING, WESTERN; CELL LINE, TUMOR; CYCLODEXTRINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPARIN; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; PRPSC PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFATES;

EID: 69949103566     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2009.07.011     Document Type: Article

References (46)

1. Prusiner S.B. Prions. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 13363-13383
2. Gambetti P., Dong Z., Yuan J., Xiao X., Zheng M., Alshekhlee A., Castellani R., Cohen M., Barria M.A., Gonzalez-Romero D., Belay E.D., Schonberger L.B., Marder K., Harris C., Burke J.R., Montine T., Wisniewski T., Dickson D.W., Soto C., Hulette C.M., Mastrianni J.A., Kong Q., and Zou W.Q. A novel human disease with abnormal prion protein sensitive to protease. Ann. Neurol. 63 (2008) 697-708
3. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81 (2001) 741-766
4. Parkin E.T., Watt N.T., Hussain I., Eckman E.A., Eckman C.B., Manson J.C., Baybutt H.N., Turner A.J., and Hooper N.M. Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 11062-11067
5. Lauren J., Gimbel D.A., Nygaard H.B., Gilbert J.W., and Strittmatter S.M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457 (2009) 1128-1132
6. Dermaut B., Croes E.A., Rademakers R., Van den Broeck M., Cruts M., Hofman A., van Duijn C.M., and Van Broeckhoven C. PRNP Val129 homozygosity increases risk for early-onset Alzheimer's disease. Ann. Neurol. 53 (2003) 409-412
7. Riemenschneider M., Klopp N., Xiang W., Wagenpfeil S., Vollmert C., Muller U., Forstl H., Illig T., Kretzschmar H., and Kurz A. Prion protein codon 129 polymorphism and risk of Alzheimer disease. Neurology 63 (2004) 364-366
8. Collinge J., Whitfield J., McKintosh E., Beck J., Mead S., Thomas D.J., and Alpers M.P. Kuru in the 21st century-an acquired human prion disease with very long incubation periods. Lancet 367 (2006) 2068-2074
9. Stewart L.A., Rydzewska L.H., Keogh G.F., and Knight R.S. Systematic review of therapeutic interventions in human prion disease. Neurology 70 (2008) 1272-1281
10. Ludewigs H., Zuber C., Vana K., Nikles D., Zerr I., and Weiss S. Therapeutic approaches for prion disorders. Expert Rev. Anti Infect. Ther. 5 (2007) 613-630
11. Priola S.A., Raines A., and Caughey W.S. Porphyrin and phthalocyanine antiscrapie compounds. Science 287 (2000) 1503-1506
12. Soler L., Caffrey P., and McMahon H.E. Effects of new amphotericin analogues on the scrapie isoform of the prion protein. Biochim. Biophys. Acta 1780 (2008) 1162-1167
13. Dealler S., and Rainov N.G. Pentosan polysulfate as a prophylactic and therapeutic agent against prion disease. IDrugs 6 (2003) 470-478
14. Farquhar C., Dickinson A., and Bruce M. Prophylactic potential of pentosan polysulphate in transmissible spongiform encephalopathies. Lancet 353 (1999) 117
15. Oboznaya M.B., Gilch S., Titova M.A., Koroev D.O., Volkova T.D., Volpina O.M., and Schatzl H.M. Antibodies to a nonconjugated prion protein peptide 95-123 interfere with PrP(Sc) propagation in prion-infected cells. Cell Mol. Neurobiol. 27 (2007) 271-284
16. Pankiewicz J., Prelli F., Sy M.S., Kascsak R.J., Kascsak R.B., Spinner D.S., Carp R.I., Meeker H.C., Sadowski M., and Wisniewski T. Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur. J. Neurosci. 23 (2006) 2635-2647
17. Prior M., Lehmann S., Sy M.S., Molloy B., and McMahon H.E. Cyclodextrins inhibit replication of scrapie prion protein in cell culture. J. Virol. 81 (2007) 11195-11207
18. Weissmann C. The state of the prion. Nat. Rev. Microbiol. 2 (2004) 861-871
19. Wong C., Xiong L.W., Horiuchi M., Raymond L., Wehrly K., Chesebro B., and Caughey B. Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein. EMBO J. 20 (2001) 377-386
20. Deleault N.R., Lucassen R.W., and Supattapone S. RNA molecules stimulate prion protein conversion. Nature 425 (2003) 717-720
21. DebBurman S.K., Raymond G.J., Caughey B., and Lindquist S. Chaperone-supervised conversion of prion protein to its protease-resistant form. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 13938-13943
22. Sc-like proteinase K-resistant conformation under physiological conditions. Biochemistry 46 (2007) 7045-7053
23. Larramendy-Gozalo C., Barret A., Daudigeos E., Mathieu E., Antonangeli L., Riffet C., Petit E., Papy-Garcia D., Barritault D., Brown P., and Deslys J.P. Comparison of CR36, a new heparan mimetic, and pentosan polysulfate in the treatment of prion diseases. J. Gen. Virol. 88 (2007) 1062-1067
24. Bone I., Belton L., Walker A.S., and Darbyshire J. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Eur. J. Neurol. 15 (2008) 458-464
25. Davis M.E., and Brewster M.E. Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. Drug Discov. 3 (2004) 1023-1035
26. Yong C.W., Washington C., and Smith W. Structural behaviour of 2-hydroxypropyl-beta-cyclodextrin in water: molecular dynamics simulation studies. Pharm. Res. 25 (2008) 1092-1099
27. Weisz P.B., Joullie M.M., Hunter C.M., Kumor K.M., Zhang Z., Levine E., Macarak E., Weiner D., and Barnathan E.S. A basic compositional requirement of agents having heparin-like cell-modulating activities. Biochem. Pharmacol. 54 (1997) 149-157
28. Folkman J., Weisz P.B., Joullie M.M., Li W.W., and Ewing W.R. Control of angiogenesis with synthetic heparin substitutes. Science 243 (1989) 1490-1493
29. Li R., Liu T., Wong B.S., Pan T., Morillas M., Swietnicki W., O'Rourke K., Gambetti P., Surewicz W.K., and Sy M.S. Identification of an epitope in the C terminus of normal prion protein whose expression is modulated by binding events in the N terminus. J. Mol. Biol. 301 (2000) 567-573
30. Goldberg R.L., and Kolibas L.M. An improved method for determining proteoglycans synthesized by chondrocytes in culture. Connect Tissue Res. 24 (1990) 265-275
31. Karashima K., Taniguchi M., Nakamura T., Takasaki M., Matsuo K., Irikura M., and Irie T. Prolongation of intrathecal and sciatic nerve blocks using a complex of levobupivacaine with maltosyl-beta-cyclodextrin in rats. Anesth. Analg. 104 (2007) 1121-1128 tables of contents
32. Sharma L., and Sharma A. Influence of cyclodextrin ring substituents on folding-related aggregation of bovine carbonic anhydrase. Eur. J. Biochem. 268 (2001) 2456-2463
33. Mulloy B., and Forster M.J. Conformation and dynamics of heparin and heparan sulfate. Glycobiology 10 (2000) 1147-1156
34. Baumann R., and Rys P. Metachromatic activity of beta-cyclodextrin sulfates as heparin mimics. Int. J. Biol. Macromol. 24 (1999) 15-18
35. Templeton D.M. The basis and applicability of the dimethylmethylene blue binding assay for sulfated glycosaminoglycans. Connect Tissue Res. 17 (1988) 23-32
36. Grant A.C., Linhardt R.J., Fitzgerald G.L., Park J.J., and Langer R. Metachromatic activity of heparin and heparin fragments. Anal. Biochem. 137 (1984) 25-32
37. Hirayama F., and Uekama K. Cyclodextrin-based controlled drug release system. Adv. Drug Deliv. Rev. 36 (1999) 125-141
38. Éhen Z., Giordano F., Sztatisz J., Jicsinszky L., and Novák C. Thermal characterization of natural and modified cyclodextrins using TG-MS combined technique. J. Therm. Anal. Calorim. 80 (2005) 419-424
39. Stella V.J., and Rajewski R.A. Cyclodextrins: their future in drug formulation and delivery. Pharm. Res. 14 (1997) 556-567
40. Muller B.W., and Brauns U. Hydroxypropyl-beta-cyclodextrin derivatives: influence of average degree of substitution on complexing ability and surface activity. J. Pharm. Sci. 75 (1986) 571-572
41. Aachmann F.L., Otzen D.E., Larsen K.L., and Wimmer R. Structural background of cyclodextrin-protein interactions. Protein Eng. 16 (2003) 905-912
42. Villalonga R., Cao R., and Fragoso A. Supramolecular chemistry of cyclodextrins in enzyme technology. Chem. Rev. 107 (2007) 3088-3116
43. Ben-Zaken O., Tzaban S., Tal Y., Horonchik L., Esko J.D., Vlodavsky I., and Taraboulos A. Cellular heparan sulfate participates in the metabolism of prions. J. Biol. Chem. 278 (2003) 40041-40049
44. Kazlauskaite J., Sanghera N., Sylvester I., Venien-Bryan C., and Pinheiro T.J. Structural changes of the prion protein in lipid membranes leading to aggregation and fibrillization. Biochemistry 42 (2003) 3295-3304
45. Shaked G.M., Meiner Z., Avraham I., Taraboulos A., and Gabizon R. Reconstitution of prion infectivity from solubilized protease-resistant PrP and nonprotein components of prion rods. J. Biol. Chem. 276 (2001) 14324-14328
46. Uekama K., Hirayama F., and Irie T. Cyclodextrin drug carrier systems. Chem. Rev. 98 (1998) 2045-2076